Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEDROXYPROGESTERONE Cause Therapy cessation? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Therapy cessation have been filed in association with MEDROXYPROGESTERONE (Provera). This represents 0.1% of all adverse event reports for MEDROXYPROGESTERONE.

7
Reports of Therapy cessation with MEDROXYPROGESTERONE
0.1%
of all MEDROXYPROGESTERONE reports
0
Deaths
2
Hospitalizations

How Dangerous Is Therapy cessation From MEDROXYPROGESTERONE?

Of the 7 reports, 2 (28.6%) required hospitalization, and 1 (14.3%) were considered life-threatening.

Is Therapy cessation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEDROXYPROGESTERONE. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does MEDROXYPROGESTERONE Cause?

Meningioma (1,364) Drug dose omission by device (510) Device leakage (500) Incorrect dose administered by device (410) Drug ineffective (403) Off label use (390) Syringe issue (354) Needle issue (346) Headache (288) Device occlusion (284)

What Other Drugs Cause Therapy cessation?

DALFAMPRIDINE (4,580) ETANERCEPT (2,031) ADALIMUMAB (1,712) ABIRATERONE (1,602) VOXELOTOR (1,038) CLOZAPINE (885) LOMITAPIDE (828) CAPECITABINE (746) TREPROSTINIL (743) ISOTRETINOIN (633)

Which MEDROXYPROGESTERONE Alternatives Have Lower Therapy cessation Risk?

MEDROXYPROGESTERONE vs MEDROXYPROGESTERONE\MEDROXYPROGESTERONE MEDROXYPROGESTERONE vs MEFENAMIC ACID MEDROXYPROGESTERONE vs MEFLOQUINE MEDROXYPROGESTERONE vs MEGESTROL MEDROXYPROGESTERONE vs MEGLUMINE

Related Pages

MEDROXYPROGESTERONE Full Profile All Therapy cessation Reports All Drugs Causing Therapy cessation MEDROXYPROGESTERONE Demographics